Citation: Yanyan Yin, Jun Guo, Shuo Zhang, Meng Xu, Yun Fu, Mengyi Zhang, Zhipeng Ma, Jiajia Ji, Siyuan Wu, Jinjie Zhang, Jianbo Li, Lei Wang. Research progress and prospect of tumor nanovaccine combination therapy strategy[J]. Chinese Chemical Letters, ;2025, 36(10): 110771. doi: 10.1016/j.cclet.2024.110771 shu

Research progress and prospect of tumor nanovaccine combination therapy strategy

Yanyan Yin ^{a, 1,} ,
Jun Guo ^{a, 1} ,
Shuo Zhang ^c ,
Meng Xu ^b ,
Yun Fu ^a ,
Mengyi Zhang ^c ,
Zhipeng Ma ^c ,
Jiajia Ji ^c ,
Siyuan Wu ^d ,
Jinjie Zhang ^{b, *,} ,
Jianbo Li ^{c, *,} ,
Lei Wang ^{b, *,}

a.
School of Pharmacy, Xinxiang Medical University, Xinxiang 453003, China
b.
Henan Key Laboratory of Nanomedicine for Targeting Diagnosis and Treatment, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China
c.
Henan Key Laboratory for Pharmacology of Liver Diseases, Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450052, China
d.
The First Clinical School of Medicine, Zhengzhou University, Zhengzhou 450001, China

yinyanyan@xxmu.edu.cn

liger1029@126.com

jb2926@126.com

wanglei1@zzu.edu.cn

Received Date: 14 October 2024
Revised Date: 12 December 2024
Accepted Date: 17 December 2024
Available Online: 18 December 2024

Figures(4)

Cancer remains one of the major threats to public health. Traditional chemotherapy, radiotherapy, and other anti-tumor therapies have numerous limitations in clinical treatment. Notwithstanding the considerable advances made in recent years with regard to immunotherapy in both basic research and clinical practice, there remains scope for further improvement, particularly with respect to its efficacy against solid tumors. With advancements in nanotechnology, tumor nanovaccines hold immense potential for preventing tumor recurrence and treating metastatic tumors. Nevertheless, the considerable heterogeneity of tumor immunogenicity presents a number of significant challenges in the development of nanometre-scale vaccines targeting solid tumors. Recent findings indicate that immune checkpoint inhibitor (ICI) therapy can improve the immunosuppressive microenvironment within tumors, while nanovaccines can also augment tumor sensitivity toward ICIs. Consequently, combining tumor nanovaccine with ICI therapy holds promise for effectively eradicating tumors or controlling their recurrence and metastasis during cancer treatment. This review delves into the mechanism behind combining tumor nanovaccine with ICI while focusing on factors influencing this combined therapy approach. Moreover, it offers an overview of the current research status regarding the combination of tumor nanovaccines with chemotherapy, radiotherapy, photothermal therapy, and sonodynamic therapy, as well as prospects for future developments in this field.
- Tumor nanovaccine,
- Immune checkpoint inhibitor,
- Combination therapy,
- Immunosuppressive microenvironment,
- Nano-carrier
1. [1]
  F. Bray, M. Laversanne, H. Sung, et al., CA Cancer J. Clin. 74 (2024) 229–263. doi: 10.3322/caac.21834
2. [2]
  E.L. Yang, Z.J. Sun, Adv. Healthc. Mater. 13 (2024) e2303294. doi: 10.1002/adhm.202303294
3. [3]
  X. Wu, Y. Li, M. Wen, et al., Chem. Soc. Rev. 53 (2024) 2643–2692. doi: 10.1039/d3cs00673e
4. [4]
  A. Zhang, T. Fan, Y. Liu, et al., Mol. Cancer 23 (2024) 251. doi: 10.1007/s40843-023-2720-6
5. [5]
  M. De Martino, J.C. Rathmell, L. Galluzzi, C. Vanpouille-Box, Nat. Rev. Immunol. 24 (2024) 654–669. doi: 10.1038/s41577-024-01026-4
6. [6]
  S. Bagchi, R. Yuan, E.G. Engleman, Annu. Rev. Pathol. 16 (2021) 223–249. doi: 10.1146/annurev-pathol-042020-042741
7. [7]
  I. Kaushik, S. Ramachandran, C. Zabel, S. Gaikwad, S.K. Srivastava, Semin. Cancer Biol. 86 (2022) 491–498. doi: 10.1016/j.semcancer.2022.03.020
8. [8]
  M.S. Carlino, J. Larkin, G.V. Long, Lancet 398 (2021) 1002–1014. doi: 10.1016/S0140-6736(21)01206-X
9. [9]
  M. Saxena, S.H. van der Burg, C.J.M. Melief, N. Bhardwaj, Nat. Rev. Cancer 21 (2021) 360–378. doi: 10.1038/s41568-021-00346-0
10. [10]
  C.S. Shemesh, J.C. Hsu, I. Hosseini, et al., Mol. Ther. 29 (2021) 555–570. doi: 10.1016/j.ymthe.2020.09.038
11. [11]
  X. Zhang, L. Zhu, H. Zhang, S. Chen, Y. Xiao, Front. Immunol. 13 (2022) 927153. doi: 10.3389/fimmu.2022.927153
12. [12]
  M. Ernst, A. Oeser, B. Besiroglu, J. Caro-Valenzuela, et al., Cochrane Database Syst. Rev. 9 (2021) Cd013365.
13. [13]
  F. Yang, C. Shay, M. Abousaud, et al., J. Exp. Clin. Cancer Res. 42 (2023) 4. doi: 10.1186/s13046-022-02568-y
14. [14]
  S. Upadhaya, S.T. Neftelino, J.P. Hodge, et al., Nat. Rev. Drug Discov. 20 (2021) 168–169. doi: 10.1038/d41573-020-00204-y
15. [15]
  M. Vorla, U.A. Akbar, A. Ashraf, et al., J. Clin. Oncol. 40 (2022) e16020. doi: 10.1200/jco.2022.40.16_suppl.e16020
16. [16]
  K.M. Heinhuis, W. Ros, M. Kok, et al., Ann. Oncol. 30 (2019) 219–235. doi: 10.1093/annonc/mdy551
17. [17]
  M. Yi, X. Zheng, M. Niu, et al., Mol. Cancer 21 (2022) 28. doi: 10.1186/s12943-021-01489-2
18. [18]
  R.C. Sterner, R.M. Sterner, Blood Cancer J. 11 (2021) 69. doi: 10.1038/s41408-021-00459-7
19. [19]
  B. Chen, L. Gong, J. Feng, et al., Chin. Chem. Lett. 35 (2024) 109432. doi: 10.1016/j.cclet.2023.109432
20. [20]
  Y. Xie, X. Li, J. Wu, et al., Chin. Chem. Lett. 34 (2023) 108202. doi: 10.1016/j.cclet.2023.108202
21. [21]
  Q. Li, Z. Teng, J. Tao, et al., Small 18 (2022) e2201108. doi: 10.1002/smll.202201108
22. [22]
  G. Garrido, B. Schrand, A. Levay, et al., Cancer Immunol. Res. 8 (2020) 856–868. doi: 10.1158/2326-6066.cir-20-0020
23. [23]
  Y. Chen, J. Zhu, J. Ding, et al., Chin. Chem. Lett. 35 (2024) 108706. doi: 10.1016/j.cclet.2023.108706
24. [24]
  Y. Wu, Z. Zhang, Y. Wei, Z. Qian, X. Wei, Chin. Chem. Lett. 34 (2023) 108098. doi: 10.1016/j.cclet.2022.108098
25. [25]
  Q. Li, M. Dang, J. Tao, et al., Adv. Funct. Mater. 34 (2024) 2311480. doi: 10.1002/adfm.202311480
26. [26]
  L. Qin, H. Zhang, Y. Zhou, C.S. Umeshappa, H. Gao, Small 17 (2021) e2006000. doi: 10.1002/smll.202006000
27. [27]
  N. Desai, V. Chavda, T.R.R. Singh, N.D. Thorat, L.K. Vora, Small 20 (2024) e2401631. doi: 10.1002/smll.202401631
28. [28]
  Z. Xu, H. Zhou, T. Li, et al., Drug Resist. Updat. 75 (2024) 101098. doi: 10.1016/j.drup.2024.101098
29. [29]
  A. Brandenburg, A. Heine, P. Brossart, Trends Cancer 10 (2024) 749–769. doi: 10.1016/j.trecan.2024.06.003
30. [30]
  O. Demaria, S. Cornen, M. Daëron, et al., Nature 574 (2019) 45–56. doi: 10.1038/s41586-019-1593-5
31. [31]
  T. Cai, H. Liu, S. Zhang, J. Hu, L. Zhang, J. Nanobiotechnol. 19 (2021) 389. doi: 10.1142/9789811218309_bmatter
32. [32]
  A. Qu, M. Sun, L. Xu, et al., Small Methods 8 (2024) e2301332. doi: 10.1002/smtd.202301332
33. [33]
  T. Feng, J. Hu, J. Wen, et al., J. Hematol. Oncol. 17 (2024) 115. doi: 10.1186/s13045-024-01628-4
34. [34]
  H. Alemohammad, B. Najafzadeh, Z. Asadzadeh, et al., Biomed. Pharmacother. 146 (2022) 112516. doi: 10.1016/j.biopha.2021.112516
35. [35]
  M. Oladejo, W. Paulishak, L. Wood, Semin. Cancer Biol. 88 (2023) 81–95. doi: 10.1016/j.semcancer.2022.12.003
36. [36]
  C. Liu, X. Liu, X. Xiang, et al., Nat. Nanotechnol. 17 (2022) 531–540. doi: 10.1038/s41565-022-01098-0
37. [37]
  Z. Li, H. Cai, Z. Li, et al., Bioact. Mater. 21 (2023) 299–312.
38. [38]
  S. Zhang, Y. Feng, M. Meng, et al., Biomaterials 289 (2022) 121794. doi: 10.1016/j.biomaterials.2022.121794
39. [39]
  W. Becker, P.B. Olkhanud, N. Seishima, et al., J. Immunother. Cancer 12 (2024) e008970. doi: 10.1136/jitc-2024-008970
40. [40]
  C. Peres, A.I. Matos, B. Carreira, et al., Adv. Funct. Mater. 34 (2024) 2401749. doi: 10.1002/adfm.202401749
41. [41]
  J. Lu, Z. Guo, R. Zheng, et al., ACS Appl. Mater. Interfaces 14 (2022) 4995–5008. doi: 10.1021/acsami.1c21946
42. [42]
  Y. Gu, S. Lin, Y. Wu, et al., Adv. Healthc. Mater. 12 (2023) e2300028. doi: 10.1002/adhm.202300028
43. [43]
  S. Shen, Y. Gao, Z. Ouyang, et al., J. Control. Release 355 (2023) 171–183. doi: 10.1016/j.jconrel.2023.01.076
44. [44]
  D.J. Gross, N.K. Chintala, R.G. Vaghjiani, et al., J. Thorac. Oncol. 17 (2022) 89–102. doi: 10.1016/j.jtho.2021.09.009
45. [45]
  S. Shang, J. Liu, V. Verma, et al., Cancer Commun. 41 (2021) 1086–1099. doi: 10.1002/cac2.12226
46. [46]
  N.K. Verma, B.H.S. Wong, Z.S. Poh, et al., EBioMedicine 83 (2022) 104216. doi: 10.1016/j.ebiom.2022.104216
47. [47]
  X. Zhao, Y. Zheng, Y. Liu, et al., ACS Nano 18 (2024) 32088–32102. doi: 10.1021/acsnano.4c10688
48. [48]
  P.D.A. Vignali, K. DePeaux, M.J. Watson, et al., Nat. Immunol. 24 (2023) 267–279. doi: 10.1038/s41590-022-01379-9
49. [49]
  Y. Zhang, H. Chen, H. Mo, et al., Cancer Cell 39 (2021) 1578-1593.e1578.
50. [50]
  R.N. Amaria, M. Postow, E.M. Burton, et al., Nature 611 (2022) 155–160. doi: 10.1038/s41586-022-05368-8
51. [51]
  A.L. Cheng, C. Hsu, S.L. Chan, S.P. Choo, M. Kudo, J. Hepatol. 72 (2020) 307–319. doi: 10.1016/j.jhep.2019.09.025
52. [52]
  S. Li, W. Yu, F. Xie, et al., Nat. Commun. 14 (2023) 8. doi: 10.1038/s41467-022-35431-x
53. [53]
  L.H. Butterfield, Y.G. Najjar, Nat. Rev. Immunol. 24 (2024) 399–416. doi: 10.1038/s41577-023-00973-8
54. [54]
  Y. Nakamura, K. Namikawa, Y. Kiniwa, et al., Eur. J. Cancer 176 (2022) 78–87. doi: 10.1016/j.ejca.2022.08.030
55. [55]
  T.A. Yap, E.E. Parkes, W. Peng, et al., Cancer Discov. 11 (2021) 1368–1397. doi: 10.1158/2159-8290.cd-20-1209
56. [56]
  J. Choi, H. Jang, J. Choi, et al., J. Control. Release 359 (2023) 85–96. doi: 10.1016/j.jconrel.2023.05.031
57. [57]
  R. Birnboim-Perach, I. Benhar, Int. J. Biol. Sci. 20 (2024) 3911–3922. doi: 10.7150/ijbs.93697
58. [58]
  T. Kang, Y. Huang, Q. Zhu, et al., Biomaterials 164 (2018) 80–97. doi: 10.1016/j.biomaterials.2018.02.033
59. [59]
  X. Zhao, J. Zhang, B. Chen, et al., Small Methods 7 (2023) e2201595. doi: 10.1002/smtd.202201595
60. [60]
  P. Ji, X.C. Deng, X.K. Jin, et al., Adv. Healthc. Mater. 12 (2023) 2300323. doi: 10.1002/adhm.202300323
61. [61]
  C. Song, H. Phuengkham, Y.S. Kim, et al., Nat. Commun. 10 (2019) 3745. doi: 10.1038/s41467-019-11730-8
62. [62]
  Y. Zhao, K.W. Wucherpfennig, Clin. Cancer Res. 30 (2024) 5527–5534. doi: 10.1158/1078-0432.ccr-23-3296
63. [63]
  L. Zhang, S. Wang, J. Xu, et al., Exp. Hematol. Oncol. 10 (2021) 16. doi: 10.1117/12.2587444
64. [64]
  F. Chen, T. Li, H. Zhang, et al., Adv. Mater. 35 (2023) e2209910. doi: 10.1002/adma.202209910
65. [65]
  W.H. Li, J.Y. Su, Y.M. Li, Acc. Chem. Res. 55 (2022) 2660–2671. doi: 10.1021/acs.accounts.2c00360
66. [66]
  X. Hu, T. Wu, X. Qin, et al., Adv. Healthc. Mater. 8 (2019) e1800837. doi: 10.1002/adhm.201800837
67. [67]
  I. Salewski, S. Kuntoff, A. Kuemmel, et al., Cancer Immunol. Immunother. 70 (2021) 3405–3419. doi: 10.1007/s00262-021-02933-4
68. [68]
  X. Jia, B. Yan, X. Tian, et al., Int. J. Biol. Sci. 17 (2021) 3281–3287. doi: 10.7150/ijbs.60782
69. [69]
  J. Ding, Y. Zheng, G. Wang, J. Zheng, D. Chai, Biochim. Biophys. Acta Rev. Cancer 1877 (2022) 188763. doi: 10.1016/j.bbcan.2022.188763
70. [70]
  D.C. Ziogas, C. Theocharopoulos, T. Koutouratsas, J. Haanen, H. Gogas, Cancer Treat. Rev. 113 (2023) 102499. doi: 10.1016/j.ctrv.2022.102499
71. [71]
  M.W. Rohaan, T.H. Borch, J.H. van den Berg, et al., N. Engl. J. Med. 387 (2022) 2113–2125. doi: 10.1056/nejmoa2210233
72. [72]
  F. Zhou, M. Qiao, C. Zhou, Cell Mol. Immunol. 18 (2021) 279–293. doi: 10.1038/s41423-020-00577-5
73. [73]
  X. Pan, S. Ni, K. Hu, Biomaterials 306 (2024) 122481. doi: 10.1016/j.biomaterials.2024.122481
74. [74]
  F.G. Ozbay Kurt, S. Lasser, I. Arkhypov, J. Utikal, V. Umansky, J. Clin. Invest. 133 (2023) e170762. doi: 10.1172/JCI170762
75. [75]
  A.C. Huang, R. Zappasodi, Nat. Immunol. 23 (2022) 660–670. doi: 10.1038/s41590-022-01141-1
76. [76]
  E.Y. Kim, H. Ner-Gaon, J. Varon, et al., J. Clin. Invest. 130 (2020) 3238–3252. doi: 10.1172/jci128075
77. [77]
  X. Zhou, Y. Wang, Z. Dou, et al., Nat. Cancer 5 (2024) 1607–1621. doi: 10.1038/s43018-024-00830-0
78. [78]
  R. Verbeke, I. Lentacker, K. Breckpot, et al., ACS Nano 13 (2019) 1655–1669.
79. [79]
  M. Jiang, L. Zhao, X. Cui, et al., J. Adv. Res. 35 (2022) 49–60. doi: 10.1016/j.jare.2021.08.011
80. [80]
  G. Zhan, Q. Xu, Z. Zhang, et al., Nano Today 38 (2021) 101195. doi: 10.1016/j.nantod.2021.101195
81. [81]
  Y.T. Qin, X.H. Liu, J.X. An, et al., ACS Nano 17 (2023) 24947–24960. doi: 10.1021/acsnano.3c06784
82. [82]
  J. Zhang, J. Fan, M. Skwarczynski, et al., Int. J. Nanomed. 17 (2022) 869–900. doi: 10.2147/ijn.s269986
83. [83]
  N. Gong, Y. Zhang, X. Teng, et al., Nat. Nanotechnol. 15 (2020) 1053–1064. doi: 10.1038/s41565-020-00782-3
84. [84]
  Z. Guo, Y. Liu, Q. Ling, et al., Am. J. Transplant. 24 (2024) 1837–1856. doi: 10.1016/j.ajt.2024.04.007
85. [85]
  M. Lesouhaitier, C. Dudreuilh, M. Tamain, et al., Eur. J. Cancer 96 (2018) 111–114. doi: 10.1016/j.ejca.2018.03.019
86. [86]
  X. Song, R. Chen, J. Li, et al., Pharmacol. Res. 206 (2024) 107297. doi: 10.1016/j.phrs.2024.107297
87. [87]
  A. Hatzioannou, A. Banos, T. Sakelaropoulos, et al., Nat. Immunol. 21 (2020) 75–85. doi: 10.1038/s41590-019-0555-2
88. [88]
  C. Tay, A. Tanaka, S. Sakaguchi, Cancer Cell 41 (2023) 450–465. doi: 10.1016/j.ccell.2023.02.014
89. [89]
  J.E. Kenison, N.A. Stevens, F.J. Quintana, Nat. Rev. Immunol. 24 (2024) 338–357. doi: 10.1038/s41577-023-00970-x
90. [90]
  T. Kaiho, H. Suzuki, A. Hata, et al., Front. Pharmacol. 14 (2023) 1298085. doi: 10.3389/fphar.2023.1298085
91. [91]
  A.S. Kittai, H. Oldham, J. Cetnar, M. Taylor, J. Immunother. 40 (2017) 277–281. doi: 10.1097/cji.0000000000000180
92. [92]
  E.J. Lipson, S.M. Bagnasco, J. Moore, et al., N. Engl. J. Med. 374 (2016) 896–898. doi: 10.1056/NEJMc1509268
93. [93]
  S. Herz, T. Höfer, M. Papapanagiotou, et al., Eur. J. Cancer 67 (2016) 66–72. doi: 10.1016/j.ejca.2016.07.026
94. [94]
  H.H. Kwok, J. Yang, D.C. Lam, Cancers 15 (2023) 2749. doi: 10.3390/cancers15102749
95. [95]
  A.J. Cooper, L.V. Sequist, J.J. Lin, Nat. Rev. Clin. Oncol. 19 (2022) 499–514. doi: 10.1038/s41571-022-00639-9
96. [96]
  S.J. McKee, B.L. Doff, M.S. Soon, S.R. Mattarollo, Cancer Immunol. Res. 5 (2017) 191–197. doi: 10.1158/2326-6066.CIR-16-0249
97. [97]
  X. Xie, Y. Feng, H. Zhang, et al., Bioact. Mater. 16 (2022) 107–119.
98. [98]
  Y. Kim, S. Kang, H. Shin, et al., Angew. Chem. Int. Ed. 59 (2020) 14628–14638. doi: 10.1002/anie.202006117
99. [99]
  A.M. Rothschilds, K.D. Wittrup, Trends Immunol. 40 (2019) 12–21. doi: 10.1016/j.it.2018.11.003
100. [100]
  L. Cucolo, Q. Chen, J. Qiu, et al., Immunity 55 (2022) 671-685.e610.
101. [101]
  C.W. Wong, C. Evangelou, K.N. Sefton, et al., Nat. Commun. 14 (2023) 5983. doi: 10.1038/s41467-023-41737-1
102. [102]
  J. Han, M. Wu, Z. Liu, Front. Immunol. 14 (2023) 1190333. doi: 10.3389/fimmu.2023.1190333
103. [103]
  Z. Zhang, X. Liu, D. Chen, J. Yu, Signal Transduct. Target Ther. 7 (2022) 258. doi: 10.1038/s41392-022-01102-y
104. [104]
  L. Hammerich, T.U. Marron, R. Upadhyay, et al., Nat. Med. 25 (2019) 814–824. doi: 10.1038/s41591-019-0410-x
105. [105]
  W. Wang, H. Xu, Q. Ye, et al., Nat. Biomed. Eng. 6 (2022) 44–53. doi: 10.1038/s41551-021-00834-6
106. [106]
  H. Luo, H. Cao, H. Jia, et al., Adv. Healthc. Mater. 12 (2023) 2301083. doi: 10.1002/adhm.202301083
107. [107]
  H. Luo, W. Ma, Q. Chen, Z. Yang, Y. Dai, Nano Today 53 (2023) 102042. doi: 10.1016/j.nantod.2023.102042
108. [108]
  C.N. Coleman, I. Eke, A.Y. Makinde, et al., Clin. Cancer Res. 26 (2020) 5781–5790. doi: 10.1158/1078-0432.ccr-20-0572
109. [109]
  M. Luo, Z. Liu, X. Zhang, et al., J. Control. Release 300 (2019) 154–160. doi: 10.1016/j.jconrel.2019.02.036
110. [110]
  S. Gou, W. Liu, S. Wang, et al., Nano Lett. 21 (2021) 9939–9950. doi: 10.1021/acs.nanolett.1c03243
111. [111]
  D. Bitounis, E. Jacquinet, M.A. Rogers, M.M. Amiji, Nat. Rev. Drug Discov. 23 (2024) 281–300. doi: 10.1038/s41573-023-00859-3
112. [112]
  C.L. O’Leary, N. Pierce, S.P. Patel, J. Naidoo, J. Thorac. Oncol. 19 (2024) 395–408. doi: 10.1016/j.jtho.2023.11.018
113. [113]
  L. Chen, W. Tang, J. Liu, et al., Biomaterials 315 (2024) 122956.
114. [114]
  C. Huang, X. Yang, Q. Yu, L. Zhang, D. Zhu, Chin. Chem. Lett. 35 (2024) 109680. doi: 10.1016/j.cclet.2024.109680
115. [115]
  V. Giannakeas, D.W. Lim, S.A. Narod, JAMA Oncol. 10 (2024) 1228–1236. doi: 10.1001/jamaoncol.2024.2212
116. [116]
  C. Cullinane, R.M. Connolly, M. Corrigan, H.P. Redmond, C. Foley, Eur. J. Immunol. 54 (2024) e2451049. doi: 10.1002/eji.202451049
117. [117]
  D. He, H. Li, Y. Li, et al., Nanoscale 15 (2023) 6252–6262. doi: 10.1039/d2nr06692k
118. [118]
  A. Dongre, M. Rashidian, E.N. Eaton, et al., Cancer Discov. 11 (2021) 1286–1305. doi: 10.1158/2159-8290.cd-20-0603
119. [119]
  Y. Liu, Y. Hu, J. Xue, et al., Mol. Cancer 22 (2023) 145. doi: 10.1186/s12943-023-01850-7
120. [120]
  Z. Wang, T. Sha, J. Li, et al., Bioact. Mater. 39 (2024) 612–629.
121. [121]
  Y.P. Jia, K. Shi, F. Yang, et al., Adv. Funct. Mater. 30 (2020) 2001059. doi: 10.1002/adfm.202001059
122. [122]
  X. Liu, Q. Su, H. Song, et al., Biomaterials 275 (2021) 120921. doi: 10.1016/j.biomaterials.2021.120921
123. [123]
  C. Zheng, X. Liu, Y. Kong, et al., Acta Pharm. Sin. B 12 (2022) 3398–3409. doi: 10.1016/j.apsb.2022.02.026
124. [124]
  T. Li, G. Chen, Z. Xiao, et al., Nano Lett. 22 (2022) 3095–3103. doi: 10.1021/acs.nanolett.2c00500
125. [125]
  C. Ji, J. Si, Y. Xu, et al., Theranostics 11 (2021) 8587–8604. doi: 10.7150/thno.62572
126. [126]
  S. Liang, J. Yao, D. Liu, et al., Adv. Mater. 35 (2023) e2211130. doi: 10.1002/adma.202211130
127. [127]
  M. Tian, Y. Li, Y. Li, et al., Small 20 (2024) e2400654. doi: 10.1002/smll.202400654
128. [128]
  Q. Zhao, Y. Zhao, S. Zhong, et al., Chin. Chem. Lett. 35 (2024) 109644. doi: 10.1016/j.cclet.2024.109644
129. [129]
  M. Pan, D. Hu, L. Yuan, et al., Acta Pharm. Sin. B 13 (2023) 2926–2954. doi: 10.1016/j.apsb.2022.12.021
130. [130]
  V.G. Collins, D. Hutton, K. Hossain-Ibrahim, J. Joseph, S. Banerjee, Br. J. Cancer 132 (2025) 409–420. doi: 10.1038/s41416-024-02898-y
131. [131]
  S. Chen, T. Ma, J. Wang, et al., Biomaterials 305 (2024) 122456. doi: 10.1016/j.biomaterials.2023.122456
132. [132]
  H. Cui, W. Zhu, C. Yue, et al., Chin. Chem. Lett. 35 (2024) 109727. doi: 10.1016/j.cclet.2024.109727
133. [133]
  S. Zuo, Y. Zhang, Z. Wang, J. Wang, Int. J. Nanomed. 17 (2022) 989–1002. doi: 10.2147/ijn.s348618
134. [134]
  L. Cai, C. Hu, S. Liu, et al., Bioconjug. Chem. 32 (2021) 661–666. doi: 10.1021/acs.bioconjchem.1c00039
135. [135]
  W. Zhao, Q. Ding, B. Zhou, et al., Adv. Funct. Mater. 34 (2024) 2407626. doi: 10.1002/adfm.202407626
136. [136]
  M. Wang, Z. Hou, S. Liu, et al., Small 17 (2021) e2005728. doi: 10.1002/smll.202005728
137. [137]
  L. Cui, H. Yao, F. Xue, et al., Aggregate 5 (2024) e504. doi: 10.1002/agt2.504
138. [138]
  T. Deng, D. Chen, F. Chen, et al., Acta Biomater. 190 (2024) 548–559. doi: 10.1016/j.actbio.2024.10.025
139. [139]
  S. Yang, M.K. Shim, W.J. Kim, et al., Biomaterials 272 (2021) 120791. doi: 10.1016/j.biomaterials.2021.120791
140. [140]
  Z. Wang, F. Miao, L. Gu, et al., ACS Nano 18 (2024) 24219–24235. doi: 10.1021/acsnano.4c05657
141. [141]
  M.M. Awad, R. Govindan, K.N. Balogh, et al., Cancer Cell 40 (2022) 1010-1026.e1011.
142. [142]
  J. Nakata, Y. Nakae, M. Kawakami, et al., Br. J. Haematol. 182 (2018) 287–290. doi: 10.1111/bjh.14768
143. [143]
  W.J. Storkus, D. Maurer, Y. Lin, et al., J. Immunother. Cancer 9 (2021) e003675. doi: 10.1136/jitc-2021-003675
144. [144]
  R. Li, Y. Hao, K. Roche, et al., Biomaterials 301 (2023) 122290. doi: 10.1016/j.biomaterials.2023.122290
145. [145]
  G. Chen, X. Li, R. Li, et al., ACS Nano 17 (2023) 18818–18831. doi: 10.1021/acsnano.3c03274
146. [146]
  L. Zhang, J. Zhang, L. Xu, et al., J. Nanobiotechnol. 19 (2021) 142. doi: 10.1186/s12951-021-00880-x
147. [147]
  X. Li, Y. Zhang, X. Wu, et al., Small 18 (2022) e2203100. doi: 10.1002/smll.202203100
148. [148]
  L. Jin, D. Yang, Y. Song, et al., ACS Nano 16 (2022) 15226–15236. doi: 10.1021/acsnano.2c06560
149. [149]
  Q.V. Le, J. Suh, J.J. Choi, et al., ACS Nano 13 (2019) 7442–7462. doi: 10.1021/acsnano.9b02071
150. [150]
  Y. Li, K. Zhang, Y. Wu, et al., Small 18 (2022) e2107461. doi: 10.1002/smll.202107461
151. [151]
  Y. Zhang, Q. Li, M. Ding, et al., Adv. Healthc. Mater. 12 (2023) e2203028. doi: 10.1002/adhm.202203028
152. [152]
  D. Zhang, P. Liu, X. Qin, et al., J. Mater. Chem. B 10 (2022) 8750–8759. doi: 10.1039/d2tb01483a
153. [153]
  B. Xiao, D. Li, H. Xu, et al., Biomaterials 274 (2021) 120893. doi: 10.1016/j.biomaterials.2021.120893
154. [154]
  Q. Liu, T. Fan, Y. Zheng, et al., Nanoscale 12 (2020) 19939–19952. doi: 10.1039/d0nr05953f
155. [155]
  X. Li, X. Wang, A. Ito, N.M. Tsuji, Nat. Commun. 11 (2020) 3858. doi: 10.1038/s41467-020-17637-z
156. [156]
  Q. Ni, F. Zhang, Y. Liu, et al., Sci. Adv. 6 (2020) eaaw6071. doi: 10.1126/sciadv.aaw6071
157. [157]
  R. Zhang, L. Tang, Y. Wang, et al., Adv. Sci. 10 (2023) e2300116. doi: 10.1002/advs.202300116
158. [158]
  H. Ye, K. Wang, J. Zhao, et al., ACS Nano 17 (2023) 10637–10650. doi: 10.1021/acsnano.3c01733
159. [159]
  J. Chen, H. Fang, Y. Hu, et al., Bioact. Mater. 7 (2022) 167–180. doi: 10.3390/horticulturae8020167
160. [160]
  H. Liu, H. Chen, Z. Liu, et al., Biomaterials 255 (2020) 120158. doi: 10.1016/j.biomaterials.2020.120158
161. [161]
  Z. Meng, Y. Zhang, J. She, et al., Nano Lett. 21 (2021) 1228–1237. doi: 10.1021/acs.nanolett.0c03646
162. [162]
  Y. Li, Y. Luo, L. Hou, et al., Adv. Healthc. Mater. 12 (2023) e2202871. doi: 10.1002/adhm.202202871
163. [163]
  Y. Zhang, J. Chen, L. Shi, F. Ma, Mater. Horiz. 10 (2023) 361–392. doi: 10.1039/D2MH01358D
164. [164]
  W. Xiao, F. Wang, Y. Gu, et al., Chin. Chem. Lett. 35 (2024) 108755. doi: 10.1016/j.cclet.2023.108755
165. [165]
  F. Hu, J. Qi, Y. Lu, et al., Chin. Chem. Lett. 34 (2023) 108250. doi: 10.1016/j.cclet.2023.108250
166. [166]
  C. Xu, Y. Kang, S. Guan, et al., Chin. Chem. Lett. 34 (2023) 107825. doi: 10.1016/j.cclet.2022.107825
167. [167]
  Y. Lu, D. Cheng, B. Niu, et al., Pharmaceuticals 16 (2023) 454. doi: 10.3390/ph16030454
168. [168]
  J. Wu, X. Wang, Y. Wang, Z. Xun, S. Li, Polymers 16 (2024) 1253. doi: 10.3390/polym16091253
169. [169]
  D. Zhang, L. Liu, J. Wang, et al., Front. Pharmacol. 13 (2022) 990505. doi: 10.3389/fphar.2022.990505
170. [170]
  S. Alghareeb, K. Asare-Addo, B.R. Conway, A.O. Adebisi, J. Drug Deliv. Sci. Technol. 95 (2024) 105564. doi: 10.1016/j.jddst.2024.105564
171. [171]
  X. Cheng, R. Pan, J. Tang, et al., Int. J. Nanomed. 19 (2024) 10513–10536. doi: 10.2147/ijn.s477027
172. [172]
  Q. Liu, X. Chen, J. Jia, et al., ACS Nano 9 (2015) 4925–4938. doi: 10.1021/nn5066793
173. [173]
  S. Han, W. Ma, D. Jiang, et al., J. Nanobiotechnol. 19 (2021) 394. doi: 10.1186/s12951-021-01116-8
174. [174]
  Y. Huang, B. Huang, D. Ye, et al., Acta Biomater. 175 (2024) 226–239. doi: 10.3847/1538-4357/ad822e
175. [175]
  J. Ren, P. Hu, E. Ma, et al., Appl. Mater. Today 27 (2022) 101445. doi: 10.1016/j.apmt.2022.101445
176. [176]
  J. Zhao, Y. Xu, S. Ma, et al., Adv. Mater. 34 (2022) e2109254. doi: 10.1002/adma.202109254
177. [177]
  J. Li, Y. Wu, J. Xiang, et al., Chem. Eng. J. 456 (2023) 140930. doi: 10.1016/j.cej.2022.140930
178. [178]
  J. Casper, S.H. Schenk, E. Parhizkar, et al., J. Control. Release 362 (2023) 667–691. doi: 10.1016/j.jconrel.2023.09.001
179. [179]
  X. Yang, Y. Wei, L. Zheng, et al., J. Mater. Chem. B 10 (2022) 8166–8180. doi: 10.1039/d2tb01358d
180. [180]
  M. Neu, O. Germershaus, M. Behe, T. Kissel, J. Control. Release 124 (2007) 69–80. doi: 10.1016/j.jconrel.2007.08.009
181. [181]
  J. Nam, S. Son, K.S. Park, J.J. Moon, Adv. Sci. 8 (2021) 2002577. doi: 10.1002/advs.202002577
182. [182]
  M.A. Beach, U. Nayanathara, Y. Gao, et al., Chem. Rev. 124 (2024) 5505–5616. doi: 10.1021/acs.chemrev.3c00705
183. [183]
  S. Li, S. Dong, J. Wu, et al., ACS Appl. Mater. Interfaces 15 (2023) 7878–7886. doi: 10.1021/acsami.2c22363
184. [184]
  Q. Jiang, M. Xie, R. Chen, et al., Front. Immunol. 13 (2022) 973601. doi: 10.3389/fimmu.2022.973601
185. [185]
  D. Wang, S. Wang, Z. Zhou, et al., Adv. Healthc. Mater. 11 (2022) e2101349. doi: 10.1002/adhm.202101349
186. [186]
  Z. Sun, R. Zhou, J. Liu, et al., Chem. Eng. J. 497 (2024) 154506. doi: 10.1016/j.cej.2024.154506
187. [187]
  S. Xiao, M. Mu, C. Feng, S. Pan, N. Chen, J. Nanobiotechnol. 22 (2024) 536. doi: 10.1186/s12951-024-02793-x
188. [188]
  Y. Li, J. Cui, C. Li, et al., Chin. Chem. Lett. 34 (2023) 108180. doi: 10.1016/j.cclet.2023.108180
189. [189]
  H.Y. Chen, J. Deng, Y. Wang, et al., Acta Biomater. 112 (2020) 1–13. doi: 10.1016/j.actbio.2020.05.028
190. [190]
  C.H. Xu, P.J. Ye, Y.C. Zhou, et al., Acta Biomater. 105 (2020) 1–14. doi: 10.1016/j.actbio.2020.01.036
191. [191]
  S. Wang, Y. Duan, Q. Zhang, et al., Small Struct. 1 (2020) 2000018. doi: 10.1002/sstr.202000018
192. [192]
  H. Wu, G. Cao, M. Liu, et al., Chin. Chem. Lett. 36 (2025) 110493. doi: 10.1016/j.cclet.2024.110493
193. [193]
  Y. Wang, C. Zhang, S. Han, et al., Chin. Chem. Lett. 35 (2024) 109578. doi: 10.1016/j.cclet.2024.109578
194. [194]
  Y. Ren, H. Jing, Y. Zhou, et al., Chin. Chem. Lett. 34 (2023) 108161. doi: 10.1016/j.cclet.2023.108161
195. [195]
  R. Yang, J. Xu, L. Xu, et al., ACS Nano 12 (2018) 5121–5129. doi: 10.1021/acsnano.7b09041
196. [196]
  A. Veillette, J. Chen, Trends Immunol. 39 (2018) 173–184. doi: 10.1016/j.it.2017.12.005
197. [197]
  S. Liu, J. Wu, Y. Feng, et al., Bioact. Mater. 22 (2023) 211–224.
198. [198]
  E. Kianfar, J. Nanobiotechnol. 19 (2021) 159. doi: 10.1186/s12951-021-00896-3
199. [199]
  Z. Wang, K. Zhi, Z. Ding, et al., Semin. Cancer Biol. 69 (2021) 77–90. doi: 10.1016/j.semcancer.2019.11.012
200. [200]
  A. Spada, J. Emami, J.A. Tuszynski, A. Lavasanifar, Mol. Pharm. 18 (2021) 1862–1894. doi: 10.1021/acs.molpharmaceut.1c00046
201. [201]
  Y. Verma, I. Khan, S. Khanna, et al., Eur. Polymer J. 220 (2024) 113427. doi: 10.1016/j.eurpolymj.2024.113427
202. [202]
  J. Huang, R. Kong, Y. Li, et al., Chin. Chem. Lett. 35 (2024) 109254. doi: 10.1016/j.cclet.2023.109254
203. [203]
  H. Ji, G. Wu, Y. Li, et al., Adv. Healthc. Mater. 9 (2020) e1901203. doi: 10.1002/adhm.201901203
204. [204]
  K. Ni, G. Lan, W. Lin, ACS Cent. Sci. 6 (2020) 861–868. doi: 10.1021/acscentsci.0c00397
205. [205]
  F. Shen, Y. Fang, Y. Wu, et al., J. Nanobiotechnol. 21 (2023) 20. doi: 10.1186/s12951-023-01771-z
206. [206]
  S. Zhou, F. Jia, Y. Wei, et al., Adv. Funct. Mater. 34 (2024) 2314012. doi: 10.1002/adfm.202314012
207. [207]
  P. Hao, L. Yang, Y. Yan, et al., Adv. Compos. Hybrid Mater. 7 (2024) 200. doi: 10.1007/s42114-024-01030-1
208. [208]
  C. Liu, Y. Wang, Y. Bao, Y. Lin, Chin. Chem. Lett. 36 (2025) 110652. doi: 10.1016/j.cclet.2024.110652
209. [209]
  Y. Li, X. Zhang, S. Liu, et al., Chin. Chem. Lett. 36 (2025) 110501. doi: 10.1016/j.cclet.2024.110501
210. [210]
  M. Lv, M. Chen, R. Zhang, et al., Cell Res. 30 (2020) 966–979. doi: 10.1038/s41422-020-00395-4
211. [211]
  H. Zhang, C. Liang, X. Ding, et al., Chin. Chem. Lett. 36 (2025) 110525. doi: 10.1016/j.cclet.2024.110525
212. [212]
  Y. Cai, Y. Jiang, Y. Chen, et al., Chin. Chem. Lett. 36 (2025) 110437. doi: 10.1016/j.cclet.2024.110437
213. [213]
  P. Wang, Y. Wang, H. Li, et al., Acta Biomater. 177 (2024) 400–413. doi: 10.1016/j.actbio.2024.02.003
214. [214]
  P. Gao, Y. Chen, Q. He, et al., Chin. Chem. Lett. 36 (2025) 110585. doi: 10.1016/j.cclet.2024.110585
215. [215]
  J. Li, H. Ren, Q. Qiu, X. Yang, et al., ACS Nano 16 (2022) 16909–16923. doi: 10.1021/acsnano.2c06926
216. [216]
  Y. Huang, Y. Ruan, Y. Ma, et al., Front. Immunol. 14 (2023) 1128840. doi: 10.3389/fimmu.2023.1128840
217. [217]
  M. Kermanian, S. Nadri, P. Mohammadi, et al., J. Control. Release 359 (2023) 326–346. doi: 10.1016/j.jconrel.2023.06.002
218. [218]
  Q. Shi, W. Zhang, Y. Zhou, et al., Biomaterials 306 (2024) 122480. doi: 10.1016/j.biomaterials.2024.122480
219. [219]
  H. Zhang, W. Chen, K. Gong, J. Chen, ACS Appl. Mater. Interfaces 9 (2017) 31519–31525. doi: 10.1021/acsami.7b09583
220. [220]
  X. Zhong, Y. Zhang, L. Tan, et al., J. Control. Release 300 (2019) 81–92. doi: 10.1016/j.jconrel.2019.02.035
1. [1]
  Tingting Hu , Chao Shen , Xueyan Wang , Fengbo Wu , Zhiyao He . Tumor microenvironment-sensitive polymeric nanoparticles for synergetic chemo-photo therapy. Chinese Chemical Letters, 2024, 35(11): 109562-. doi: 10.1016/j.cclet.2024.109562
2. [2]
  Peng Gao , Yuanyuan Chen , Qianlin He , Xue Liu , Echuan Tan , Zhiqiang Yu , Hui Wang . Highly efficient adoptive cell therapy of metastatic triple negative breast cancer with bioactive covalent organic framework-engineered macrophages. Chinese Chemical Letters, 2025, 36(8): 110585-. doi: 10.1016/j.cclet.2024.110585
3. [3]
  Lijuan Liu , Zhihao Zhao , Feiwan Zou , Wukun Liu , Yunlong Lu . Advances in combination therapy for the treatment of estrogen receptor positive breast cancer. Chinese Chemical Letters, 2025, 36(10): 111451-. doi: 10.1016/j.cclet.2025.111451
4. [4]
  Ningyue Xu , Jun Wang , Lei Liu , Changyang Gong . Injectable hydrogel-based drug delivery systems for enhancing the efficacy of radiation therapy: A review of recent advances. Chinese Chemical Letters, 2024, 35(8): 109225-. doi: 10.1016/j.cclet.2023.109225
5. [5]
  Hao Sun , Shengke Li , Qian Liu , Minzan Zuo , Xueqi Tian , Kaiya Wang , Xiao-Yu Hu . Supramolecular prodrug vesicles for selective antimicrobial therapy employing a chemo-photodynamic strategy. Chinese Chemical Letters, 2025, 36(3): 109999-. doi: 10.1016/j.cclet.2024.109999
6. [6]
  Wenbin Zhou , Yafei Gao , Xinyu Feng , Yanqing Zhang , Cong Yang , Lanxi He , Fenghe Zhang , Xiaoguang Li , Qing Li . Biomimetic nanoplatform integrates FRET-enhanced photodynamic therapy and chemotherapy for cascaded revitalization of the tumor immune microenvironment in OSCC. Chinese Chemical Letters, 2025, 36(1): 109763-. doi: 10.1016/j.cclet.2024.109763
7. [7]
  Fengyun Li , Zerong Pei , Shuting Chen , Gen li , Mengyang Liu , Liqin Ding , Jingbo Liu , Feng Qiu . Multifunctional nano-herb based on tumor microenvironment for enhanced tumor therapy of gambogic acid. Chinese Chemical Letters, 2024, 35(5): 108752-. doi: 10.1016/j.cclet.2023.108752
8. [8]
  Shuheng Zhang , Yuanyuan Zhang , Wanyu Wang , Yuzhu Hu , Xinchuan Chen , Bilan Wang , Xiang Gao . A combination strategy of DOX and VEGFR-2 targeted inhibitor based on nanomicelle for enhancing lymphoma therapy. Chinese Chemical Letters, 2024, 35(12): 109658-. doi: 10.1016/j.cclet.2024.109658
9. [9]
  Li Fu , Ziye Su , Shuyang Wu , Yanfen Cheng , Chuan Hu , Jinming Zhang . Redox-responsive hyaluronic acid-celastrol prodrug micelles with glycyrrhetinic acid co-delivery for tumor combination therapy. Chinese Chemical Letters, 2025, 36(5): 110227-. doi: 10.1016/j.cclet.2024.110227
10. [10]
  Zhiqiang Cui , Dongxiang Zhang , Yanru Huang , Chunyu Shao , Yiming Zhang , Changliang Sun , Xin-Dong Jiang , Xiaohong Sun , Qinghuan Xiao . Novel 1-phenylethyl-containing aza-BDOIPY for phototherapy and simultaneous monitoring of tumor immune microenvironment reprogramming. Chinese Chemical Letters, 2025, 36(7): 110460-. doi: 10.1016/j.cclet.2024.110460
11. [11]
  Honghao Sun , Huimin Zhao , Ronghui Yin , Chenxi Zhou , Ming Wu , Yueyang Deng , Zhanwei Zhou , Minjie Sun . Injectable hydrogel-based tumor vaccine with fibrotic tumor immune microenvironment remodeling to prevent breast cancer postoperative recurrence and metastases. Chinese Chemical Letters, 2025, 36(5): 110067-. doi: 10.1016/j.cclet.2024.110067
12. [12]
  Hanyong Wang , Weijia Zhang , Chenlu Huang , Xinyu Yang , Qingyu Yu , Hai Wang , Wen Li , Linhua Zhang , Dunwan Zhu . Personalized tumor vaccines based on carrier-free double-adjuvant nanoparticles and tumor-associated antigens for enhancing immune responses. Chinese Chemical Letters, 2025, 36(7): 111092-. doi: 10.1016/j.cclet.2025.111092
13. [13]
  Guanghui Lin , Jieyao Chen , Xiaojia Liu , Yitong Lin , Xudong Zhu , Guotao Yuan , Bowen Yang , Shuanshuan Guo , Yue Pan , Jianhua Zhou . Sustained modulation of tumor microenvironment via sorafenib-loaded mesoporous ferromanganese nanozymes for enhanced apoptosis-ferroptosis cancer therapy. Chinese Chemical Letters, 2025, 36(8): 111018-. doi: 10.1016/j.cclet.2025.111018
14. [14]
  Li Li , Jiale Wen , Xiaojun Zhang , Shuwen Fu , Zixuan Chen , Kai Huang , Luyue Fang , Tinghe Zhao , Peipei Zhang , Xingshu Li . A near-infrared naphthalocyanine photosensitizer with superior light absorption and renal clearance for type-Ⅰ photodynamic and photothermal combination therapy. Chinese Chemical Letters, 2025, 36(6): 110290-. doi: 10.1016/j.cclet.2024.110290
15. [15]
  Yang Liu , Minglu Li , Jianxun Ding , Xuesi Chen . Glycoengineering-assistant biomineralization for tumor blockade therapy. Chinese Chemical Letters, 2025, 36(5): 110146-. doi: 10.1016/j.cclet.2024.110146
16. [16]
  Yi Cao , Xiaojiao Ge , Yuanyuan Wei , Lulu He , Aiguo Wu , Juan Li . Tumor microenvironment-activatable neuropeptide-drug conjugates enhanced tumor penetration and inhibition via multiple delivery pathways and calcium deposition. Chinese Chemical Letters, 2024, 35(4): 108672-. doi: 10.1016/j.cclet.2023.108672
17. [17]
  Yanfei Liu , Yaqin Hu , Yifu Tan , Qiwen Chen , Zhenbao Liu . Tumor acidic microenvironment activatable DNA nanostructure for precise cancer cell targeting and inhibition. Chinese Chemical Letters, 2025, 36(1): 110289-. doi: 10.1016/j.cclet.2024.110289
18. [18]
  Qiuxia Tan , E Pang , Qin Wang , Yuanyu Tang , Pan Zhu , Shaojing Zhao , Jianing Yi , Shiguang Jin , Minhuan Lan . Manganese carbonate-based nanoplatform for starvation therapy cascaded chemodynamic therapy, enhanced phototherapy and immune activation. Chinese Chemical Letters, 2025, 36(10): 110770-. doi: 10.1016/j.cclet.2024.110770
19. [19]
  Ruifeng Liang , Yanbei Tu , Peng Hua , Yongzhuo Huang , Meiwan Chen . ROS-responsive micelles co-loaded dexamethasone and pristimerin to restore the homeostasis of the inflammatory microenvironment for rheumatoid arthritis therapy. Chinese Chemical Letters, 2025, 36(6): 110335-. doi: 10.1016/j.cclet.2024.110335
20. [20]
  Tao LIU , Yuting TIAN , Ke GAO , Xuwei HAN , Ru'nan MIN , Wenjing ZHAO , Xueyi SUN , Caixia YIN . A photothermal agent with high photothermal conversion efficiency and high stability for tumor therapy. Chinese Journal of Inorganic Chemistry, 2024, 40(8): 1622-1632. doi: 10.11862/CJIC.20240107

Get Citation

PDF

XML

Metrics

PDF Downloads(0)
Abstract views(80)
HTML views(0)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142